Iol Chemicals & Pharmaceuticals Ltd. · NSE:IOLCP
Iol Chemicals & Pharmaceuticals — Q4 FY2021 Earnings Presentation
24 slides from Iol Chemicals & Pharmaceuticals's earnings presentation, June 2021
Slide 1: IOL Chemicals and Pharmaceuticals Limited Investor Presentation
IOL Chemicals and Pharmaceuticals Limited Investor Presentation June 2021
Slide 2: Disclaimer
Disclaimer This information may contain certain forward-looking statements/details in the current scenario, which is extremely dynamic and increasingly fraught with risks and uncertainties. Actual results, performances, achievements or sequence of events may be materially different from the views ex
Slide 3: About IOL Chemicals and Pharmaceuticals Limited
About IOL Chemicals and Pharmaceuticals Limited Incorporated in 1986, IOLCP is one of the leading Pharmaceuticals company and is a significant player in the field of specialty chemicals with world class facilities Catering to the top-tier players across diverse important industries like pharmaceutic
Slide 4: Key Highlights
Key Highlights Team size of 2,000+ Largest producer of Largest producer of Ethyl 2nd Largest producer of Over 20 products are employees Ibuprofen and the only Acetate at Single Location Iso Butyl Benzene (IBB) commercialised with 8 company worldwide being in India with ~30% Global share products in
Slide 5: Professional Management Team
Professional Management Team Mr. Varinder is an industrialist and has wide and rich Mr. Vikas is academically equipped with the experience of more than 35 years in the chemical & knowledge and possesses organizational capacity. He fertilizer industry and along with a comprehensive has worked in stra
Slide 6: Experienced Independent Directors
Experienced Independent Directors Rajender Mohan Malla Dr. Sandhya Mehta Harpal Singh (Chairman and Independent (Independent Director) (Independent Director) Director) • Mr. Rajender has very distinguished career • Dr. Sandhya is working as the principal of • Mr. Harpal has had over 35 year's of fou
Slide 7: Our Journey
Our Journey Unit-08 for Multi Unit-06 for Pantoprazole Unit-03 for new Products 2020 (Dedicated) 2018 product facility 2012 Unit-07 Metformin Unit-04 Metformin Unit-02 for Ibuprofen 2021 (Dedicated) 2019 (Dedicated) 2016 (Dedicated) Unit-05 Clopidogrel & Fenofibrate Unit-01 Ibuprofen (Dedicated) Lis
Slide 8: Certifications and Accreditations
Certifications and Accreditations Approved USFDA Ibuprofen EUGMP Certification in Certificate of Suitability Certificate of Suitability facility since 2015, 2013, 2017 & from EDQM for from EDQM for recertified in 2019 Recertification in 2020 IBUPROFEN, CEP No. 316- LAMOTRIGINE, CEP No. 2008 066-2013
Slide 9: Product Segmentation
Product Segmentation 9
Slide 10: Business Segment – Pharmaceuticals
Business Segment – Pharmaceuticals IOLCP is the largest producer of Ibuprofen with ~35% Global share and the only company worldwide being backward integrated for all Intermediates and Key Starting Material of Ibuprofen Among the largest Added more than 7 new Product portfolio that producer of Metfor
Slide 11: Pharmaceuticals Product Portfolio – Commercialized & Pipeline
Pharmaceuticals Product Portfolio – Commercialized & Pipeline API - Commercialized API - Pipeline Ibuprofen Fexofenadine Ibuprofen Lysinate Ibuprofen Sodium Quetiapine Fumarate Dex-Ibuprofen Dextromethorphan Metformin HCL Clopidogrel Bisulphate (Form II) Apixaban Pantoprazole Sodium Fenofibrate (Mic
Slide 12: Pharmaceuticals Product wise Segmentation – Quarterly & Annually
Pharmaceuticals Product wise Segmentation – Quarterly & Annually Q4FY21 Q4FY20 FY21 FY20 2% 4% 3% 3% 1% 5% 5% 4% 3% 4% 2% 4% 6% 6% 8% 12% 77% 85% 82% 86% Clopidogrel Other Pharma Ibuprofen Metformin Pantaprazole Bisulphate Products 12
Slide 13: Business Segment – Specialty Chemicals
Business Segment – Specialty Chemicals IOLCP first commenced manufacturing Ethyl Acetate in 1996, with a starting capacity of 3000 tonnes per annum. Today, the Company has grown this business to become the largest single location plant in India, with a production capacity of 100,000 tonnes per annum
Slide 14: Chemicals Product wise Segmentation – Quarterly & Annually
Chemicals Product wise Segmentation – Quarterly & Annually Q4FY21 Q4FY20 FY21 FY20 18% 25% 24% 24% 75% 76% 76% 82% Ethyl Acetate Other Chemicals 14
Slide 15: Manufacturing Facility spread across over 100 acres with GMP approved guidelines
Manufacturing Facility spread across over 100 acres with GMP approved guidelines API manufactured in batch manner and Facility is coupled with ISO class-8 HVAC intermediates & Specialty chemicals in Dedicated blocks involved in manufacturing system, PSA Nitrogen & Purified water along continuous pro
Slide 16: Our Core Sustainability Pillars
Our Core Sustainability Pillars Oxygen plant donated by IOLCP to the Civil Hospital Barnala • Strive to minimize the adverse impact on • Construction and renovation of school locations, environment, health and Safety by upgrading provided technical equipment for smart education technology, optimum u
Slide 17: Financial Overview
Financial Overview 17
Slide 18: Key Financial Summary
Key Financial Summary Financial Summary Q4FY21 Q4FY20 FY21 FY20 (INR Cr) Total Income 466 447 1991 1910 Gross Profit 189 204 888 845 EBITDA 117 142 616 590 PAT 75 90 445 361 18 All Profits and Total Income include Other Income
Slide 19: 5 years Financial Performance - Annually
5 years Financial Performance - Annually Revenues & Margins* – Annual Margin* Expansion – Over the Years 2,000 1,910 1,991 50% 50% Gross % 1,800 1,696 45% 45% 45% 45% 12% 1,600 44% 40% 40% EBITDA % 1,400 33% 38% 31% 31% 35% 35% 33% 30% 31% 1,200 25% 30% 30% 16% 990 22% PAT % 22% 1,000 25% 25% 19% 80
Slide 20: 5 years Geographical Segmental Breakup - Annual
5 years Geographical Segmental Breakup - Annual In INR crs 1,600 1,400 1,354 1,250 1,200 1,038 1,000 800 633 647 644 613 600 484 400 350 227 200 - FY17 FY18 FY19 FY20 FY21* Domestic Export 20 *FY21 Covid Impact
Slide 21: Financial Summary – Balance Sheet
Financial Summary – Balance Sheet Balance Sheet (INR Crs) FY17 FY18 FY19 FY20 FY21 Shareholder's Funds 189 216 474 813 1260 Debt 446 422 284 56 - Other Long Term Liabilities 17 34 21 80 59 Other Current Liabilities 165 181 163 221 291 Equity & Liabilities 817 852 942 1170 1610 Fixed Assets 395 413 4
Slide 22: Financial Summary – Statement of Profit and Loss
Financial Summary – Statement of Profit and Loss P&L (INR Crs) FY17 FY18 FY19 FY20 FY21 Q4FY20 Q4FY21 Revenues 711 983 1,685 1,894 1,967 442 460 Other Income 1 7 11 16 24 5 6 Total Income 712 990 1,696 1,910 1,991 447 466 Gross Profits 234 294 648 845 888 204 189 Gross Profits %* 33% 30% 38% 44% 45%
Slide 23: Shareholder Information
Shareholder Information Stock Data (As on 31st March, 2021) Shareholding Pattern (%) Market Capitalization (₹) 3,232Crs 55.2% 50.3% Face Value(₹) 10 41.9% 43.7% Share Price (₹) 550 EPS (₹) 76 52-Week High (₹) 898 6.0% 2.9% 52-Week Low (₹) 174 Promoter Institutional Others Symbol(NSE/BSE) IOLCP | 524
Slide 24: Thank You
Thank You For further details: Mr. Pardeep Kumar Khanna , CFO Email: pardeepkhanna@iolcp.com Phone: +91-161-2225531-35
IOL Chemicals and Pharmaceuticals — Q4 FY2021 Earnings Presentation on 6ix